GCC-targeted CAR-T shows 33% response rate in heavily pretreated colorectal cancer
A 24-patient phase 1 trial of non-armored GCC-targeting CAR-T cells found a 33% response rate but two treatment-related deaths, underscoring a tolerability problem still unresolved.
Executive Summary
- A phase 1 trial evaluated non-armored, nanobody-derived CAR-T cells targeting guanylate cyclase C (GCC) in patients with metastatic colorectal cancer who had already failed multiple prior treatments.
- The therapy produced objective tumor responses in about a third of patients and disease control in nearly two-thirds, a proof-of-concept result for a tumor-forming cancer indication where cell therapies have struggled to show activity.
- Toxicity was pronounced across the cohort: every patient developed severe blood-count declines, most developed cytokine release syndrome, and two patients died from treatment-related complications, one from an immune-mediated inflammatory syndrome and one from a bowel injury tied to rapid tumor shrinkage.
- The data support further investigation of GCC as a CAR-T target in colorectal cancer, but responses were not durable and the path forward depends on dose selection, patient eligibility criteria, and better toxicity management.
The stake
Colorectal cancer that has progressed after multiple lines of chemotherapy has few effective options, and cell therapies engineered from CAR-T cells have shown activity mainly against blood cancers rather than tumors that form masses in organs and tissue. This trial tested whether targeting guanylate cyclase C, a receptor expressed on colorectal tumor cells, could extend CAR-T activity into that harder tumor setting. The therapy used a non-armored construct, meaning the T cells were not additionally engineered with cytokine or other support genes beyond the CAR itself, and was derived from a nanobody rather than a conventional antibody fragment. Non-ArmoredNon-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer.Jul 17, 2026
How it was done
The trial was a single-arm, open-label phase 1 study (no control group, no blinding) that enrolled 24 patients with metastatic colorectal cancer who had received at least two prior lines of treatment. Patients received GCC-targeted CAR-T cells at one of four escalating dose levels, from 0.5×10^5 to 3×10^6 cells per kilogram. The primary endpoint was safety; secondary endpoints covered antitumor activity and pharmacokinetics, including how the CAR-T cells expanded and persisted in patients' blood. Non-ArmoredNon-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer.Jul 17, 2026
The results
The overall response rate reached 33% and the disease control rate reached 63%, with eight patients achieving a partial response, seven maintaining stable disease, and five progressing. Median progression-free survival was 57 days and median overall survival was 190 days, indicating that most responses did not persist for long even when they occurred. Higher in vivo CAR-T expansion was associated with better disease control, a pharmacokinetic signal linking cell persistence to clinical benefit. Non-ArmoredNon-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer.Jul 17, 2026
The safety signal
All 24 patients experienced grade 3 or higher hematologic toxicity (severe drops in blood cell counts), and 75% developed cytokine release syndrome, an inflammatory reaction common to CAR-T therapies. Both were described as generally manageable, but two patients died from treatment-related causes: one from an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, a severe immune overactivation syndrome, and one from an intestinal fistula that developed after rapid tumor shrinkage in a lesion attached to the intestinal wall. The second death illustrates a mechanism-specific risk: rapid on-target tumor killing near bowel tissue can itself cause injury, distinct from the systemic inflammatory toxicities more commonly tracked in CAR-T trials. Non-ArmoredNon-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer.Jul 17, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.